IDXX financials
IDEXX Laboratories, Inc. · end-of-day data as of Oct 16, 2026
IDEXX Laboratories, Inc.
$560.36+2.9%
Buy · 14 analystsPT $755.97 +34.9%
IDXX reported revenue of $1.22B for the quarter ended Jun 30, 2026 (Q2 FY2026), up 9.7% from a year earlier. It posted diluted EPS of $4.19, free cash flow of $323M and a net margin of 27.8%.
Valuation
- P/E39.7x
- P/E vs own-12.4%
- P/E vs sector+41.0%
- FCF yield+2.8%
- Market cap$44.15B
Quarterly results
Q2 FY2026: Revenue +9.7% year over year, free cash flow 26.5% of revenue, operating margin 35.0%.
RevenueFree cash flow
| Q2 FY2026 | Jun 30, 2026 | $1.22B | 4.19 | $323M | 64.0% | 35.0% | 27.8% |
| Q1 FY2026 | Mar 31, 2026 | $1.14B | 3.45 | $234M | 63.4% | 31.8% | 24.4% |
| Q4 FY2025 | Dec 31, 2025 | $1.09B | 3.08 | $323M | 60.3% | 28.9% | 22.8% |
| Q3 FY2025 | Sep 30, 2025 | $1.11B | 3.40 | $371M | 61.8% | 32.1% | 24.8% |
| Q2 FY2025 | Jun 30, 2025 | $1.11B | 3.63 | $152M | 62.6% | 33.6% | 26.5% |
| Q1 FY2025 | Mar 31, 2025 | $998M | 2.96 | $208M | 62.4% | 31.7% | 24.3% |
| Q4 FY2024 | Dec 31, 2024 | $954M | 2.62 | $223M | 59.8% | 27.4% | 22.7% |
| Q3 FY2024 | Sep 30, 2024 | $976M | 2.80 | $192M | 61.1% | 31.2% | 23.9% |
| Q2 FY2024 | Jun 30, 2024 | $1B | 2.44 | $215M | 61.9% | 26.3% | 20.3% |
| Q1 FY2024 | Mar 31, 2024 | $964M | 2.81 | $168M | 61.5% | 31.0% | 24.4% |
| Q4 FY2023 | Dec 31, 2023 | $902M | 2.32 | $217M | 58.4% | 27.2% | 21.6% |
| Q3 FY2023 | Sep 30, 2023 | $916M | 2.53 | $238M | 59.9% | 30.1% | 23.2% |